Lumakras (Sotorasib) Patent Expiration, LOE Window & CMS Spending
Lumakras (Sotorasib) by Amgen: FDA Orange Book core substance LOE 2040-05-20 (last listed 2040-09-15), 0 AB generics, $171.9M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Amgen |
| FDA Application & Pathway | N214665 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | 2040-05-20 |
| Last Listed Patent or Exclusivity Date | 2040-09-15 |
| Orange Book Patents (*PED Extensions) | 6 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 0 |
| 2024 CMS Total Public Spend | $171.9M |
| 2024 Medicare Part D Spend | $153.6M |
| 2024 Medicaid Spend | $18.3M |
| Reported Wholesale Price Change (CA SB 17) | 2 WAC filings (max 18.0% 2-yr change) |
Related Filings Across Meru Platforms
Verified cross-ledger federal filings for Amgen across sibling Meru public-data platforms.